A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.
Long-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone.
MRD-positive patients in first complete remission after induction therapy had a survival benefit after transplant; however, that benefit did not extend to MRD-negative patients after transplant.